Creative Medical Technology Holdings, Inc. (CELZ)
After hours:
| Previous Close | 2.9000 |
| Open | 2.9800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.8300 - 3.0000 |
| 52 Week Range | 2.6500 - 10.2812 |
| Volume | |
| Avg. Volume | 7,943 |
| Market Cap | 4.014M |
| Beta (5Y Monthly) | 5.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0700 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireCreative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence (AI) with the Company’s proprietary human
Simply Wall St.Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights Creative Medical Technology Holdings' Annual General Meeting to take place on 19th of July Salary of...
- GlobeNewswire
Creative Medical Technology Holdings Provides Corporate Update
PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update highlighting recent developments of note. “As we enter the second half of 2024, it is an opportune time to reflect on our recent achievements,” said Timothy Warbington, Chief Executive
